Premium Nahrungsergänzungsmittel | artgerecht

Endothelin 1 (ET-1) – Function & Clinical Significance

Endothelin 1 (ET-1) is an endogenous peptide hormone produced by vascular endothelial cells. It is one of the most potent vasoconstrictors known in the human body.

Regular tips about health Regular tips about health

Things worth knowing about "Endothelin 1"

Endothelin 1 (ET-1) is an endogenous peptide hormone produced by vascular endothelial cells. It is one of the most potent vasoconstrictors known in the human body.

What is Endothelin 1?

Endothelin 1 (ET-1) is a biologically active peptide consisting of 21 amino acids. It is primarily produced by endothelial cells – the cells lining the inner walls of blood vessels. ET-1 belongs to the endothelin family (ET-1, ET-2, ET-3) and is considered one of the most potent vasoconstrictors known, meaning it causes powerful narrowing of blood vessels. It plays a central role in regulating blood pressure and vascular tone.

Mechanism of Action

Endothelin 1 exerts its effects by binding to specific receptors on the surface of target cells. There are two main receptor subtypes:

ETA receptor: Found primarily on vascular smooth muscle cells. Activation leads to vasoconstriction (narrowing of blood vessels) and cell proliferation.
ETB receptor: Present on both endothelial cells and smooth muscle cells. Activation on endothelial cells promotes the release of nitric oxide (NO) and prostacyclin, which counteracts excessive vasoconstriction. On smooth muscle cells, however, it also contributes to vasoconstriction.

The release of ET-1 is stimulated by various factors, including hypoxia (low oxygen levels), mechanical stress on the vessel wall, inflammatory mediators, and hormones such as angiotensin II.

Biological Functions

ET-1 performs a variety of important functions in the human body:

Vascular tone regulation: ET-1 increases peripheral resistance and contributes to blood pressure control.
Cardiac function: It influences cardiomyocytes and can increase the contractile force of the heart.
Renal physiology: ET-1 regulates kidney perfusion and sodium excretion.
Pulmonary circulation: It plays an important role in regulating pulmonary arterial pressure.
Cell proliferation: ET-1 promotes the growth and division of various cell types, which can contribute to vascular remodeling.

Clinical Significance

Excessive production or activity of Endothelin 1 is associated with a range of diseases:

Pulmonary arterial hypertension (PAH): Elevated ET-1 levels cause narrowing and structural remodeling of the pulmonary arteries, contributing significantly to the development of PAH.
Arterial hypertension: ET-1 contributes to the development and maintenance of high blood pressure.
Heart failure: In heart failure, plasma ET-1 levels are markedly elevated and correlate with disease severity.
Atherosclerosis: ET-1 promotes inflammatory processes and smooth muscle cell proliferation, contributing to arterial plaque formation.
Kidney disease: Elevated ET-1 activity is involved in the development of chronic kidney damage.
Scleroderma: In this connective tissue disorder, elevated ET-1 levels contribute to vascular changes and fibrosis.

Diagnostic Relevance

Measuring ET-1 levels in the blood can serve as a biomarker in various conditions. In pulmonary arterial hypertension in particular, plasma ET-1 levels indicate disease severity and response to therapy. Elevated ET-1 values are also found in patients with heart failure, renal insufficiency, and systemic vascular diseases.

Therapeutic Approaches

Given the central role of ET-1 in several diseases, medications have been developed that specifically block the endothelin signaling pathway. These are known as endothelin receptor antagonists:

Bosentan: Blocks both ETA and ETB receptors and is approved for the treatment of pulmonary arterial hypertension.
Ambrisentan: A selective ETA receptor antagonist, also used in PAH.
Macitentan: A newer dual endothelin receptor antagonist with improved tissue penetration, used in PAH management.

These medications improve exercise capacity and slow disease progression in patients with pulmonary arterial hypertension.

References

Yanagisawa M et al. – A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–415. DOI: 10.1038/332411a0
Rubin LJ, Roux S – Bosentan: a dual endothelin receptor antagonist. Expert Opinion on Investigational Drugs. 2002;11(7):991–1002.
Galiè N et al. – 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2016;37(1):67–119. DOI: 10.1093/eurheartj/ehv317

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.